Xconomy Q&A: An Update with Arcturus Therapeutics CEO Joseph Payne
Xconomy
OCTOBER 23, 2017
Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.
Let's personalize your content